ClinicalTrials.gg
Not yet recruitingNCT07200921TCM-ICHUpdated Oct 1, 2025

A Multicenter, Randomized, Double-blind, Placebo-controlled Trial on the Treatment of Hypertensive Intracerebral Hemorrhage With Naoxuekang Dropping Pills

A Phase 2 interventional study of Naoxuekang Dropping Pills and Naoxuekang Matching Placebo in Hypertensive Intracerebral Hemorrhage and Cerebral Small Vessel Diseases, sponsored by Beijing Tiantan Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-10-01.

Sponsored by Beijing Tiantan Hospital · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1,950
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Intracranial Hemorrhage, Hypertensive with a site in China — 4 open to participants now, 4 under way, none of them phase 3. Intracranial Hemorrhage, Hypertensive · China.

Planned enrollment
Largest of 10
1,950 · median 353
Started
2025
the only one that year
Phase 2
3 of 11
1 open now
Registered
10th of 11
by date
Lead sponsor
1 of 11
Beijing Tiantan Hospital

Among the 11 studies in Intracranial Hemorrhage, Hypertensive with a site in China, this one has the largest planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2025, is one of 3 in phase 2, and was the 10th registered.

Intracranial Hemorrhage, Hypertensive

23 studies on the registry are indexed under Intracranial Hemorrhage, Hypertensive; 8 are open to participants now.

Browse Intracranial Hemorrhage, Hypertensive studies →

Open to participants now

4 of the 11 studies in Intracranial Hemorrhage, Hypertensive with a site in China are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1 Intracranial Hemorrhage, Hypertensive study recruiting now, none set no upper age limit and 1 stops at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Intracranial Hemorrhage, Hypertensive with a site in China, or all of them as a file.
02

Study summary

This study aims to evaluate the effectiveness and safety of a Chinese medicine-based intervention combined with standard medicine, in reducing composite vascular events in patients with hypertensive intracerebral hemorrhage (HICH).This is a multicenter, randomized, double-blind, placebo-controlled trial. A total of 1950 participants with HICH within 7 days of onset, accompanied by imaging evidence of cerebral small vessel disease, will be enrolled.Participants will be randomly assigned to receive eitherNaoxuekang Dropping Pills or matching placebo for 90 days, in addition to guideline-based standard care.The primary outcome is the incidence of composite vascular events (including ischemic stroke, hemorrhagic stroke, myocardial infarction, vascular death, deep vein thrombosis, and pulmonary embolism) within 1 year.Secondary outcomes include vascular events within 90 days, neurological function (mRS), and cognitive function (MMSE, MoCA) at 90 days and 1 year.Safety will be monitored through adverse event reporting.The results will provide evidence for optimizing secondary prevention strategies in HICH patients.

03

Conditions studied

  • Hypertensive Intracerebral Hemorrhage
  • Cerebral Small Vessel Diseases

Keywords

  • Hypertensive intracerebral hemorrhage
  • Cerebral small vessel disease
  • Naoxuekang Dropping Pills
  • Randomized controlled trial
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Meets the diagnostic criteria for hypertensive intracerebral hemorrhage.
  2. Able to cooperate with a head MRI examination and has imaging manifestations of cerebral small vessel disease (CSVD) (Staals total CSVD burden score ≥ 1).
  3. Supratentorial hemorrhage (volume ≤ 30ml) or infratentorial hemorrhage (volume ≤ 10ml).
  4. Within 7 days of symptom onset.
  5. NIHSS score ≤ 25.
  6. GCS score ≥ 8.
  7. Age between 18 and 80 years (inclusive).
  8. Any gender

Exclusion criteria

Exclusion Criteria:

  1. Primary intraventricular hemorrhage.
  2. Spontaneous intracerebral hemorrhage due to other causes or secondary intracerebral hemorrhage (e.g., from trauma, vascular malformations, coagulation disorders, hematological diseases, systemic diseases, or tumors).
  3. Planned surgical intervention (including craniotomy for hematoma evacuation, minimally invasive hematoma removal, or ventricular puncture).
  4. Patients with active peptic ulcer, bleeding, or other clear tendency for rebleeding.
  5. Patients with severe hepatic or renal dysfunction (Severe hepatic dysfunction: or AST > 3 times the ; Severe renal dysfunction: Serum creatinine > 2 times the upper limit of normal).
  6. Suffering from other life-threatening severe diseases with an expected survival time of less than 1 year.
  7. Known allergy to any component of the study drug.
  8. Pregnant women, women planning pregnancy, or lactating women.
  9. Participating in another interventional clinical trial.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,950 participants (estimated)

Study arms

  • Experimental
    Experimental Group

    Participants in this group will receive Naoxuekang Dropping Pills (20 pills, three times daily) orally for 90 days, in addition to standardized guideline-based Western medical care.

    Drug: Naoxuekang Dropping Pills

  • Placebo comparator
    Control Group

    Participants in this group will receive matched placebo pills (20 pills, three times daily) orally for 90 days, in addition to standardized guideline-based Western medical care.

    Drug: Naoxuekang Matching Placebo

Interventions

  • DrugNaoxuekang Dropping Pills

    A traditional Chinese medicine. Each pill weighs 35mg. Dosage: 20 pills, three times daily, orally for 90 days.

  • DrugNaoxuekang Matching Placebo

    A placebo pill matched to Naoxuekang Dropping Pills in appearance, taste , size, and packaging. Dosage: 20 pills, three times daily, orally for 90 days.

06

What researchers measure

Primary outcomes

  1. Incidence of Composite Vascular Events

    Composite vascular events within one year of onset, including arterial vascular events (ischemic stroke, hemorrhagic stroke, myocardial infarction, vascular death) and venous vascular events (lower extremity venous thrombosis, pulmonary embolism).

    Time frame: Within 1 year after the onset of intracerebral hemorrhage.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2025; primary completion for Nov 2028, 37 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2025
First posted
Oct 1, 2025
StartEst.
Oct 10, 2025
Primary completionEst.
Nov 30, 2028
CompletionEst.
Nov 30, 2028
Last update
Oct 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07200921
Collaborators
The Affiliated Hospital of Qingdao University, Beijing Kangerfu Pharmaceutical Company Limited
Responsible party
Sponsor
First posted
Oct 1, 2025
Start date
Oct 10, 2025 (estimated)
Primary completion
Nov 30, 2028 (estimated)
Completion
Nov 30, 2028 (estimated)
Last update
Oct 1, 2025

Study contacts

Xintong Song, MD
Contact
Songxt1962@163.com
010-17519241291
Qian Zhang, MD
principal investigator · Beijing Tiantan Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion